Lupus Erythematosus, Systemic
|
0.200 |
Biomarker
|
disease |
BEFREE |
CD4+CD25+CD127dim levels showed significant association with alopecia and oral ulcers in SLE patients only, but no correlation with measured serum markers.
|
30325682 |
2019 |
Lupus Erythematosus, Systemic
|
0.200 |
Biomarker
|
disease |
BEFREE |
CD4+CD25-Foxp3+ T cells were correlated with clinical and laboratory data and the SLE Disease Activity Index (SLEDAI).
|
30154885 |
2018 |
Lupus Erythematosus, Systemic
|
0.200 |
Biomarker
|
disease |
BEFREE |
Serum soluble CD25 as a risk factor of renal impairment in systemic lupus erythematosus - a prospective cohort study.
|
29482443 |
2018 |
Lupus Erythematosus, Systemic
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
Recently, a subset of FOXP3<sup>+</sup> cells with low CD25 expression was found to be increased in peripheral blood from systemic lupus erythematosus (SLE) patients, although its functional significance remains controversial.
|
28747257 |
2017 |
Lupus Erythematosus, Systemic
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
To elucidate the origins of the SLE T<sub>reg</sub> phenotype, we studied its role through developmentally defined regulatory T cell (T<sub>reg</sub> ) subsets in 45 SLE patients, 103 SLE-unaffected first-degree relatives and 61 unrelated healthy control subjects, and genetic association with the CD25-encoding IL2RA locus.
|
28542701 |
2017 |
Lupus Erythematosus, Systemic
|
0.200 |
Biomarker
|
disease |
BEFREE |
Murine CD4+CD25-LAG3+ regulatory T cells suppress B cell function through the production of TGF-β3, and it has been reported that TGF-β3 is therapeutic in a mouse model of systemic lupus erythematosus.
|
28052118 |
2017 |
Lupus Erythematosus, Systemic
|
0.200 |
GeneticVariation
|
disease |
GWASCAT |
Meta-analysis of shared genetic architecture across ten pediatric autoimmune diseases.
|
26301688 |
2015 |
Lupus Erythematosus, Systemic
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
FoxP3(+) cells were depleted within CD4(+)CD25(+) Tregs in patients with APS (28.4%) relative to those without APS (46.3%, p = 0.008). mTOR activity was similar between SLE patients with and without APS.
|
25862984 |
2015 |
Lupus Erythematosus, Systemic
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
To replicate a single nucleotide polymorphism (SNP) of known genes for lupus (IRF5 rs10488631, PTPN22 rs2476601, BLK rs2736340 and TNFAIP3 rs5029939) and other autoimmune diseases (CD28 rs1980422, IL2RA rs2104286 and KIF5A rs1678542) on a newly studied Egyptian cohort to investigate the genetic disparity with different studied ethnic groups in relation to lupus susceptibility.
|
26092158 |
2015 |
Lupus Erythematosus, Systemic
|
0.200 |
Biomarker
|
disease |
BEFREE |
Real-time transcription-polymerase chain reaction analysis was used to determine the expression of Ets-1 and FOXP3 mRNA in CD4(+)CD25(+) Treg cells from 36 patients with SLE and 18 sex-and-age-matched healthy controls.
|
24221578 |
2014 |
Lupus Erythematosus, Systemic
|
0.200 |
Biomarker
|
disease |
BEFREE |
Herein, we found that CD4(+)CD25(high)FoxP3(+) or CD4(+)CD45RA(+)FoxP3(low) T-cells, and CD8(+)CD25(+)FoxP3(+) T-cells were all induced durably in PBMCs from inactive lupus patients and healthy subjects by the histone peptide/s themselves, but in active lupus, dexamethasone or hydroxychloroquine unmasked Treg-induction by the peptides.
|
24211843 |
2013 |
Lupus Erythematosus, Systemic
|
0.200 |
Biomarker
|
disease |
BEFREE |
Total glucosides of paeony induces regulatory CD4(+)CD25(+) T cells by increasing Foxp3 demethylation in lupus CD4(+) T cells.
|
22406048 |
2012 |
Lupus Erythematosus, Systemic
|
0.200 |
Biomarker
|
disease |
BEFREE |
These results were supported by the fact that CD4(+)CD25(high) cells from steroid-treated SLE patients did not show a higher antiproliferative function than those from non-steroid-treated patients.
|
20667622 |
2011 |
Lupus Erythematosus, Systemic
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
In addition, healthy pDCs + apoPMNs induced suppressive T regulatory cell features with increased Foxp3 expression in CD4 + CD25 + cells while SLE pDCs + apoPMNs did not.
|
20618924 |
2010 |
Lupus Erythematosus, Systemic
|
0.200 |
Biomarker
|
disease |
BEFREE |
Thus, PD-1.3A may contribute to abnormalities in PD-1 receptor expression on CD4+CD25+ T cells in patients with SLE, providing support for an important role of the PD-1 pathway in SLE and, possibly, in other autoimmune diseases.
|
20178125 |
2010 |
Lupus Erythematosus, Systemic
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
We have confirmed a previous suggestion that the IL2RA locus is associated with SLE and showed some evidence of association with AAV.
|
19265545 |
2009 |
Lupus Erythematosus, Systemic
|
0.200 |
Biomarker
|
disease |
BEFREE |
Low frequency of CD4+CD25+ Treg in SLE patients: a heritable trait associated with CTLA4 and TGFbeta gene variants.
|
19173720 |
2009 |
Lupus Erythematosus, Systemic
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
Among several proposed surface or intracellular Treg cell markers, CD25 at high level of expression and the transcription factor Foxp3 are the two most investigated in SLE.
|
19185065 |
2009 |
Lupus Erythematosus, Systemic
|
0.200 |
Biomarker
|
disease |
BEFREE |
In fresh peripheral blood, we found that decreased percentages of CD4+CD25+/CD4+ in SLE patients were associated with disease activity and renal involvement.
|
18473105 |
2008 |
Lupus Erythematosus, Systemic
|
0.200 |
Biomarker
|
disease |
BEFREE |
The alleles present at -308 TNF-alpha and -1082 IL-10 genes; serum concentrations of interferon-alpha (IFN-alpha), IL-10 and TNF-alpha; and size and function of CD4+CD25(high) (Treg) population were determined in SLE patients and in healthy controls.
|
18597405 |
2008 |
Lupus Erythematosus, Systemic
|
0.200 |
Biomarker
|
disease |
LHGDN |
We characterized CD4+CD25+CTLA-4+FoxP3+ T cells in 43 patients with systemic lupus erythematosus (SLE).
|
17712998 |
2007 |
Lupus Erythematosus, Systemic
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
We demonstrated reduced CD4(+) CD25(+) Treg levels were inversely correlated with disease activity, indicating a defective Treg population in paediatric SLE patients.
|
16423064 |
2006 |
Lupus Erythematosus, Systemic
|
0.200 |
Biomarker
|
disease |
BEFREE |
The immune regulation of lupus GN is distinct from other organ-specific diseases and not influenced by CD25(+) or NK1.1(+) regulatory T cells.
|
15238073 |
2004 |
Lupus Erythematosus, Systemic
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
Lymphocyte activation in patients with SLE was evident from the increase in CD25 expression on PBL, with a reciprocal decrease in CD122 expression.
|
8881918 |
1996 |
Lupus Erythematosus, Systemic
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
CD4+CD45RO- T cells from SLE patients co-expressed Fas antigen and early to intermediate activation antigens such as CD25 and CD71, and late activation antigen HLA-DR in only FashiCD4+ naive T cells.
|
7531628 |
1995 |